9-cyclopentyl-2-N-(4-methoxyphenyl)-8-N-phenylpurine-2,8-diamine | 1360445-27-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-cyclopentyl-2-N-(4-methoxyphenyl)-8-N-phenylpurine-2,8-diamine
• CAS: 1360445-27-7
• 化学式: C₂₃H₂₄N₆O
• 分子量: 400.483
• InChiKey: XROXTBFBPYWNOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  76.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N4-cyclopentyl-N2-(4-methoxyphenyl)pyrimidine-2,4,5-triamine 、 硫代异氰酸苯酯 在 乙醇 、 N,N'-二异丙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 9-cyclopentyl-2-N-(4-methoxyphenyl)-8-N-phenylpurine-2,8-diamine
  参考文献：
  名称：

  Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury

  摘要：

  In this Letter we describe the optimization of an aminopurine lead (1) with modest potency and poor overall kinase selectivity which led to the identification of a series of potent, selective JNK inhibitors. Improvement in kinase selectivity was enabled by introduction of an aliphatic side chain at the C-2 position. CC-359 (2) was selected as a potential clinical candidate for diseases manifested by ischemia reperfusion injury. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.028

文献信息

• Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury
  作者：Véronique Plantevin Krenitsky、Mercedes Delgado、Lisa Nadolny、Kiran Sahasrabudhe、Leticia Ayala、Steven S. Clareen、Robert Hilgraf、Ronald Albers、Adam Kois、Kevin Hughes、Jonathan Wright、Jacek Nowakowski、Elise Sudbeck、Sutapa Ghosh、Sogole Bahmanyar、Philip Chamberlain、Jeff Muir、Brian E. Cathers、David Giegel、Li Xu、Maria Celeridad、Mehran Moghaddam、Oleg Khatsenko、Paul Omholt、Jason Katz、Sema Pai、Rachel Fan、Yang Tang、Michael A. Shirley、Brent Benish、Kate Blease、Heather Raymon、Shripad Bhagwat、Ian Henderson、Andrew G. Cole、Brydon Bennett、Yoshitaka Satoh

  DOI：10.1016/j.bmcl.2011.12.028

  日期：2012.2

  In this Letter we describe the optimization of an aminopurine lead (1) with modest potency and poor overall kinase selectivity which led to the identification of a series of potent, selective JNK inhibitors. Improvement in kinase selectivity was enabled by introduction of an aliphatic side chain at the C-2 position. CC-359 (2) was selected as a potential clinical candidate for diseases manifested by ischemia reperfusion injury. (C) 2011 Elsevier Ltd. All rights reserved.